which glp 1 agonists have cardiovascular benefit and mortality outcomes with GLP-1 receptor vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Benefits and drawbacks of GLP-1

10.1056/NEJMoa1607141 [DOI] [PubMed] Associated Data This section collects any data citations, data availability statements, or supplementary materials included in this article

Insulin resistance exacerbated pathological PD features which contributed to disease progression via increases in -synuclein accumulation in dopaminergic neurons, oxidative stress, and mitochondrial dysfunction

First, clinicians should implement baseline neurological evaluations before initiating therapy, particularly in patients with pre-existing neurological comorbidities

Previous physiological studies have shown that both GIP (113116) and GLP-1 (117) act in concert with glucose to enhance insulin gene transcription, mRNA stability, insulin biosynthesis, and insulin secretion

2024;51(1) doi: 10.1007/S11033-024-09793-Y

New GLP-1 drugs could suppress desire for more than just food, study suggests A new study funded by the National Institutes of Health (NIH) has uncovered how a newer class of oral GLP-1 weight-loss drugs could reduce the desire for more than just food